Seeking Alpha

Achillion Pharmaceuticals gives HCV pipeline update, shares collapse

  • Achillion Pharmaceuticals (ACHN) gives an HCV pipeline update.
  • Sovaprevir is still on clinical hold even though the company says it has "addressed all issues noted in the FDA's June 29, 2013 letter." (previous)
  • As for the sovaprevir/ACH-3102/ribavirin combo, rapid virologic response was 79%. That doesn't appear to stack up too well with results from BMY, GILD, and ABBV if one assumes RVR is a good indicator of SVR. (more on this here)
  • Additionally, the company indicates it will advance ACH-2684 into Phase 2 combo studies. (PR)
  • ACHN -44% AH
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|